Literature DB >> 1400877

Effects of testosterone supplementation in the aging male.

J S Tenover1.   

Abstract

Serum androgen levels decline with aging in normal males, such that a significant number of men over 60 yr of age will have a mean serum total testosterone (T) level near the low end of the normal adult range. It is not known whether lower T levels in older men have an effect on androgen-responsive organ systems, such as muscle, bone, bone marrow, and prostate, nor are there data to evaluate the relative benefits and risks of T supplementation in older men. We assessed the physiological and biochemical effects of T therapy in 13 healthy men, 57-76 yr old, who had low or borderline low serum T levels (< or = 13.9 nmol/L). Intramuscular testosterone enanthate (TE; 100 mg weekly) and placebo injections were given for 3 months each. Before treatment and at the end of both 3-month treatment regimens, lean body mass, body fat, biochemical parameters of bone turnover, hematological parameters, lipoprotein profiles, and prostate parameters [such as prostate-specific antigen (PSA)] were evaluated. Serum T levels rose in all subjects with TE treatment, such that the lowest level of T during a week's period was 19.7 +/- 0.7 nmol/L (mean +/- SE). After 3 months of TE treatment, lean body mass was significantly increased, and urinary hydroxyproline excretion was significantly depressed. With TE treatment, there was a significant increase in hematocrit, a decline in total cholesterol and low density lipoprotein cholesterol, and a sustained increase in serum PSA levels. Placebo treatment led to no significant changes in any of these parameters. We conclude that short term (3 months) TE supplementation to healthy older men who have serum T levels near or below the lower limit of normal for young adult men results in an increase in lean body mass and possibly a decline in bone resorption, as assessed by urinary hydroxyproline excretion, with some effect on serum lipoproteins, hematological parameters, and PSA. The sustained stimulation of PSA and the increase in hematocrit that occur with physiological TE supplementation suggest that older men should be screened carefully and followed periodically throughout T therapy.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1400877     DOI: 10.1210/jcem.75.4.1400877

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  109 in total

1.  For and against: The male menopause--does it exist?

Authors:  D C Gould; R Petty; H S Jacobs
Journal:  BMJ       Date:  2000-03-25

Review 2.  Aging-related changes in skeletal muscle. Mechanisms and interventions.

Authors:  L Larsson; B Ramamurthy
Journal:  Drugs Aging       Date:  2000-10       Impact factor: 3.923

3.  The male menopause: does it exist?: against: problems of senescence in men are not analogous to female menopause

Authors: 
Journal:  West J Med       Date:  2000-08

Review 4.  Hormone treatment and muscle anabolism during aging: androgens.

Authors:  E Lichar Dillon; William J Durham; Randall J Urban; Melinda Sheffield-Moore
Journal:  Clin Nutr       Date:  2010-05-07       Impact factor: 7.324

Review 5.  Osteoporosis in men: are we ready to diagnose and treat?

Authors:  H M Perry; J E Morley
Journal:  Curr Rheumatol Rep       Date:  2001-06       Impact factor: 4.592

Review 6.  Andropause: to treat or not to treat?

Authors:  S Basaria; A Dobs
Journal:  J Endocrinol Invest       Date:  2003-07       Impact factor: 4.256

Review 7.  Regulation of body composition by androgens.

Authors:  S Bhasin
Journal:  J Endocrinol Invest       Date:  2003-09       Impact factor: 4.256

Review 8.  Hormone replacement therapy and physical function in healthy older men. Time to talk hormones?

Authors:  Manthos G Giannoulis; Finbarr C Martin; K Sreekumaran Nair; A Margot Umpleby; Peter Sonksen
Journal:  Endocr Rev       Date:  2012-03-20       Impact factor: 19.871

9.  Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels, low bone mass, and physical frailty.

Authors:  Anne M Kenny; Alison Kleppinger; Kristen Annis; Margaret Rathier; Bruce Browner; James O Judge; Daniel McGee
Journal:  J Am Geriatr Soc       Date:  2010-06       Impact factor: 5.562

10.  Nutrition and sarcopenia of ageing.

Authors:  Satoshi Fujita; Elena Volpi
Journal:  Nutr Res Rev       Date:  2004-06       Impact factor: 7.800

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.